These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15696439)

  • 21. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in statins and the kidney.
    Oda H; Keane WF
    Kidney Int Suppl; 1999 Jul; 71():S2-5. PubMed ID: 10412725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin therapy in cardiovascular diseases other than atherosclerosis.
    Beaudry D; Stone KE; Wetherold S; Hemphill J; Do D; McClish J; Chilton R
    Curr Atheroscler Rep; 2007 Jan; 9(1):25-32. PubMed ID: 17228487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microcirculation as a target for the anti-inflammatory properties of statins.
    Scalia R; Stalker TJ
    Microcirculation; 2002 Dec; 9(6):431-42. PubMed ID: 12483541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms.
    Bahrami A; Bo S; Jamialahmadi T; Sahebkar A
    Ageing Res Rev; 2020 Mar; 58():101024. PubMed ID: 32006687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One statin, two statins, three statins, more: similarities and differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Turkoski BB
    Orthop Nurs; 2011; 30(1):62-5; quiz 66-7. PubMed ID: 21278557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance.
    Biasucci LM; Biasillo G; Stefanelli A
    Clin Chem Lab Med; 2010 Dec; 48(12):1685-91. PubMed ID: 20868311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigations of statins in heart failure: inflammatory biomarkers and hormones.
    Khan BV; Rajagopalan S
    Heart Fail Clin; 2008 Apr; 4(2):171-6. PubMed ID: 18433697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of statins on toll-like receptors: a new insight to pleiotropic effects.
    Bahrami A; Parsamanesh N; Atkin SL; Banach M; Sahebkar A
    Pharmacol Res; 2018 Sep; 135():230-238. PubMed ID: 30120976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy insight: Potential of statins for cancer chemoprevention and therapy.
    Katz MS
    Nat Clin Pract Oncol; 2005 Feb; 2(2):82-9. PubMed ID: 16264880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.
    Yoshida T; Hayashi M
    Clin Exp Nephrol; 2017 Apr; 21(2):175-181. PubMed ID: 27294581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond the laboratory: clinical implications for statin pleiotropy.
    Halcox JP; Deanfield JE
    Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins in chronic kidney disease and kidney transplantation.
    Kassimatis TI; Goldsmith DJ
    Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of statins on renal function.
    Agarwal R
    Mayo Clin Proc; 2007 Nov; 82(11):1381-90. PubMed ID: 17976359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?
    Steffens S; Mach F
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):378-87. PubMed ID: 16932466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotropic Effects and Proposed Mechanism of Action for 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors (Statins).
    Arefieva TI; Filatova AY; Potekhina AV; Shchinova AM
    Biochemistry (Mosc); 2018 Aug; 83(8):874-889. PubMed ID: 30208827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin pleiotropy against renal injury.
    Kostapanos MS; Liberopoulos EN; Elisaf MS
    J Cardiometab Syndr; 2009; 4(1):E4-9. PubMed ID: 19245508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
    McCarey DW; Sattar N; McInnes IB
    Arthritis Res Ther; 2005; 7(2):55-61. PubMed ID: 15743490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.